A pharmacodynamic markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis

Clinical Pharmacology and Therapeutics

Volumn 86, Issue 4, 2009, Pages 387-395

  Lacroix, B D ^a,b   Lovern, M R ^a   Stockis, A ^a   Sargentini Maier, M L ^a   Karlsson, M O ^b   Friberg, L E ^b  

^a UCB PHARMA   (Belgium)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CERTOLIZUMAB PEGOL; METHOTREXATE; PLACEBO;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROBABILITY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIMULATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE FACTORS; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MARKOV CHAINS; MIDDLE AGED; PATIENT DROPOUTS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEX FACTORS; YOUNG ADULT;

EID: 70349439118     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.136     Document Type: Article

References (28)

1. Choy, E.H. & Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 344, 907-916 (2001).
2. Saxne, T., Palladino, M.A. Jr., Heinegård, D., Talal, N. & Wollheim, F.A. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31, 1041-1045 (1988).
3. Chin, J.E., Winterrowd, G.E., Krzesicki, R.F. & Sanders, M.E. Role of cytokines in inflammatory synovitis. The coordinate regulation of intercellular adhesion molecule 1 and HLA class I and class II antigens in rheumatoid synovial fibroblasts. Arthritis Rheum. 33, 1776-1786 (1990).
4. Nawroth, P.P., Bank, I., Handley, D., Cassimeris, J., Chess, L. & Stern, D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J. Exp. Med. 163, 1363-1375 (1986).
5. Butler, D.M., Maini, R.N., Feldmann, M. & Brennan, F.M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur. Cytokine Netw. 6, 225-230 (1995).
6. Haworth, C., Brennan, F.M., Chantry, D., Turner, M., Maini, R.N. & Feldmann, M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur. J. Immunol. 21, 2575-2579 (1991).
7. Scott, D.L. & Kingsley, G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 355, 704-712 (2006).
8. Genovese, M.C. et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46, 1443-1450 (2002).
9. Weinblatt, M.E. et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48, 35-45 (2003).
10. Maini, R.N. et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 50, 1051-1065 (2004).
11. Keystone, E.C. et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50, 1400-1411 (2004).
12. Nesbitt, A. et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm. Bowel Dis. 13, 1323-1332 (2007).
13. Nesbitt, A., Fossati, G., Henry, A., Palframan, R. & Stephens, S. Effect of structure of conventional anti-TNFs and certolizumab pegol on mode of action in rheumatoid arthritis. Ann. Rheum. Dis. 66 (suppl. 2), 296 (2007) (Abstract).
14. Choy, E.H. et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41, 1133-1137 (2002).
15. Fleischmann, R. et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous diseasemodifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis. 68, 805-811 (2009).
16. Keystone, E. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319-3329 (2008).
17. Smolen, J.S. et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 68, 797-804 (2009).
18. Felson, D.T. et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727-735 (1995).
19. Felson, D.T. et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 36, 729-740 (1993).
20. US Food and Drug Administration. Guidance for Industry: Clinical Development Programs for Drugs, Devices and Biological Products for the Treatment of Rheumatoid Arthritis (RA). Center for Drug Evaluation and Research, Rockville, MD, 1999.
21. Lee, H., Kimko, H.C., Rogge, M., Wang, D., Nestorov, I. & Peck, C.C. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin. Pharmacol. Ther. 73, 348-365 (2003).
22. Karlsson, M.O. et al. A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep. Clin. Pharmacol. Ther. 68, 175-188 (2000).
23. Dougados, M. et al. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Ann. Rheum. Dis. 68, 484-489 (2009).
24. Hutmacher, M.M., Krishnaswami, S. & Kowalski, K.G. Exposure-response modeling using latent variables for the efficacy of a JAK3 inhibitor administered to rheumatoid arthritis patients. J. Pharmacokinet. Pharmacodyn. 35, 139-157 (2008).
25. World Medical Association Declaration of Helsinki. 54th WMA General Assembly, Washington, DC, 2-6 October 2002.
26. Beal, S.L. & Sheiner, L.B. NONMEM User Guides (NONMEM project group, University of California, San Francisco, CA, 1992).
27. Lindbom, L., Pihlgren, P., Jonsson, E.N. & Jonsson, N. PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods. Programs. Biomed. 79, 241-257 (2005).
28. R Development Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria, 2008). ≤http://www.R-project.org>.